{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-007393","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.518812+00:00","generated_at":"2026-06-16T04:32:08.356007+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TG Therapeutics reports Q1 BRIUMVI net sales of $7.8M in first partial launch quarter","bullets":["BRIUMVI net sales $7.8M for Q1 2023; over 400 prescriptions from 165+ HCPs at 125+ centers.","Payor coverage in place for over 50% of covered lives; permanent J-code effective July 1, 2023.","Net loss narrowed to $39.2M vs $69.0M YoY; cash $139.7M with $20M credit facility, funding into mid-2024.","CHMP positive opinion for EU approval of BRIUMVI for RMS; additional data presented at ACTRIMS/AAN.","R&D expense $15.9M (down from $48M) driven by lower manufacturing/clinical costs post-approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-007393","json":"https://secwatch.observer/filing/0001558370-23-007393.json","markdown":"https://secwatch.observer/filing/0001558370-23-007393.md","text":"https://secwatch.observer/filing/0001558370-23-007393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000155837023007393/0001558370-23-007393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000155837023007393/tgtx-20230501x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:32:08.356007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}